Physician profile
Daniel C Woods
NPI 1942276159
$5,414.86
in general payments reported to CMS, 2019-2025
37 companies · $1,067 in 2025
The $1,067 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $559 · 2020: $142 · 2021: $618 · 2022: $691 · 2023: $1,032 · 2024: $1,306 · 2025: $1,067.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,355 · Long Term Medical Supply Or Device Loan: $49.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,355.31 |
| Long Term Medical Supply Or Device Loan | $49.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $896.89 | 2019-2025 | Farxiga, Airsupra |
| Amgen INC. | $813.81 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $398.92 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $358.99 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $309.97 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $242.65 | 2019-2024 | Xarelto |
| Catalyst Orthoscience | $236.42 | 2024-2025 | Catalyst Csr Shoulder System |
| Novo Nordisk INC | $222.92 | 2019-2024 | Ozempic, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $199.04 | 2019-2025 | Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $164.93 | 2022-2023 | |
| Lilly USA, LLC | $152.92 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $139.83 | 2019-2025 | Gardasil 9, Vaxneuvance, Proquad |
| Abbvie INC. | $130.20 | 2022-2025 | Vraylar |
| Novartis Pharmaceuticals Corporation | $126.08 | 2019-2023 | |
| Abbott Laboratories | $97.65 | 2021-2024 | Freestyle Insulinx, Freestyle Libre 3 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Woods listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.